Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Brandes

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Neuropsychiatric Disease and Treatment|July 15, 2010
The role of glatiramer acetate in the early treatment of multiple sclerosisDavid W Brandes
Neurology India|October 16, 2009
Invited commentary. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care settingDavid W Brandes
Current Medical Research and Opinion|August 13, 2008
Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosisHarold Moses, David W Brandes
Neurology|June 10, 2009
Redefining functionality and treatment efficacy in multiple sclerosisJohn F Foley, David W Brandes
Journal of Medical Economics|February 9, 2013
Implications of real-world adherence on cost-effectiveness analysis in multiple sclerosisDavid W Brandes, Karina Raimundo, Neetu Agashivala, et al.
The American Journal of Managed Care|July 10, 2010
Quantifying the role of natalizumab in health and economic outcomes in multiple sclerosisDavid W Brandes, Fadia T Shaya, Michael W Pill
Current Medical Research and Opinion|February 13, 2009
A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse eventsDavid W Brandes, Teri Callender, Ellen Lathi, et al.
Patient Preference and Adherence|April 27, 2013
A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimodKristin A Hanson, Neetu Agashivala, Sonja M Stringer, et al.
Current Medical Research and Opinion|June 26, 2007
Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: a pilot studyDavid W Brandes, Kim Bigley, William Hornstein, et al.
International Journal of MS Care|August 24, 2016
NAPS-MS: Natalizumab Effects on Parameters of Sleep in Patients with Multiple SclerosisRichard A Sater, Mark Gudesblatt, Kiren Kresa-Reahl, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Neuropsychiatric Disease and Treatment|July 15, 2010
The role of glatiramer acetate in the early treatment of multiple sclerosisDavid W Brandes
Neurology India|October 16, 2009
Invited commentary. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care settingDavid W Brandes
Current Medical Research and Opinion|August 13, 2008
Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosisHarold Moses, David W Brandes
Neurology|June 10, 2009
Redefining functionality and treatment efficacy in multiple sclerosisJohn F Foley, David W Brandes
Journal of Medical Economics|February 9, 2013
Implications of real-world adherence on cost-effectiveness analysis in multiple sclerosisDavid W Brandes, Karina Raimundo, Neetu Agashivala, et al.
The American Journal of Managed Care|July 10, 2010
Quantifying the role of natalizumab in health and economic outcomes in multiple sclerosisDavid W Brandes, Fadia T Shaya, Michael W Pill
Current Medical Research and Opinion|February 13, 2009
A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse eventsDavid W Brandes, Teri Callender, Ellen Lathi, et al.
Patient Preference and Adherence|April 27, 2013
A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimodKristin A Hanson, Neetu Agashivala, Sonja M Stringer, et al.
Current Medical Research and Opinion|June 26, 2007
Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: a pilot studyDavid W Brandes, Kim Bigley, William Hornstein, et al.
International Journal of MS Care|August 24, 2016
NAPS-MS: Natalizumab Effects on Parameters of Sleep in Patients with Multiple SclerosisRichard A Sater, Mark Gudesblatt, Kiren Kresa-Reahl, et al.
Pageof 2